| abstract |
PCT No. PCT/GB93/00010 Sec. 371 Date Sep. 1, 1994 Sec. 102(e) Date Sep. 1, 1994 PCT Filed Jan. 6, 1993 PCT Pub. No. WO93/14069 PCT Pub. Date Jul. 22, 1993Compounds of formula (I), wherein: A represents: a) a -VR6 group wherein v is -C(=O), -C(=O)O-, -CH2O-, -CH2OC(=O)-, -C(=S)-, -CH2OC(=O)NH-, -C(=S)O-, -CH2S-, -C(=O)NHSO2-, -SO2NHC(=O)- or -CH2OSiPh2-; b) a -CH2NR9R10 group or a -CONR9R10 group wherein each of R9 and R10 is independently hydrogen, -alkyl-, -alkenyl-, -alkynyl, -cycloalkyl, -cycloalkenyl, pyridyl (any of which may optionally be substituted) or a group -D as defined above or R9 and R10 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring; c) a group Y where Y is a 5- or 6-membered optionally substituted heterocyclic ring containing one or more heteroatoms selected from nitrogen, oxygen and sulphur; or d) a group -CH2Y or -C(=O)NHY; where Y is as defined above; B represents a 5- or 6-membered heterocyclic ring containing one or more nitrogen atoms in its ring, are antagonists of platelet activating factor (PAF) and/or antagonists of angiotensin II. |